Business Description
Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, focused on developing treatments for brain-related and rare metabolic diseases, including Parkinson's disease, Alzheimer's disease, frontotemporal dementia, and several lysosomal storage disorders. The company has built a broad pipeline of drug candidates that work through a variety of approaches, including enzyme replacement, gene therapy, and small molecule inhibitors. Originally founded in 2013 under the name SPR Pharma, Denali has grown into a clinical-stage company with multiple programs advancing through development, several of which are being pursued in partnership with large pharmaceutical companies.
